Genesys, BDC invest in Profound Medical's $17.4 mln offering

Canadian venture capital firms Genesys Capital and BDC Capital have acquired additional common shares in Profound Medical Corp (TSX-V: PRN), a Toronto medical device company focused on treatments for prostate cancer. The investments were made as part of Profound's $17.4 million bought deal offering, announced earlier this week. Genesys invested via its latest fund, Genesys Ventures III, which raised $90 million in an initial close in August. It now owns about 21.4 percent of the company's total shares. BDC announced its investment in a separate release, taking a 24.3 percent interest.

CanadaNorth AmericaBriefs